RIPK3 and cancer: Necroptosis, a regulated cell death mainly mediated by RIPK1 (receptor-interacting protein [RIP] kinase 1), RIPK3, and MLKL (mixed lineage kinase domain-like pseudokinase) (Gong et al., 2019), has recently been reported to play significant roles in regulating cancer progression and is considered to be a trigger and amplifier of antitumor immunity in cancer therapy.